Summary & Overview
Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC: Inpatient Reimbursement Overview
DRG 837 addresses inpatient chemotherapy for patients with acute leukemia as a secondary diagnosis or high dose chemotherapy agents with a Major Complication or Comorbidity, defining a higher-resource case mix for hospitals. Proper classification matters because it determines Medicare payment levels that reflect increased clinical complexity, treatment intensity, and inpatient resource needs.
DRG 837 Overview
DRG 837 covers hospital inpatient cases involving chemotherapy where acute leukemia is listed as a secondary diagnosis or where a high dose chemotherapy agent is administered and a Major Complication or Comorbidity is present. This Diagnosis-Related Group captures resource intensity associated with complex chemotherapy management, higher toxicity monitoring, and complications requiring inpatient care. It matters for Medicare payment because cases classified to this DRG typically have higher relative weights and reimbursement to reflect the added clinical complexity and resource use. Accurate coding of diagnoses, procedures, and Major Complication or Comorbidity status drives correct assignment and payment under Medicare.